GMED vs GKOS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

GMED

42.6
AI Score
VS
GMED Wins

GKOS

31.5
AI Score

Investment Advisor Scores

GMED

43score
Recommendation
HOLD

GKOS

32score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric GMED GKOS Winner
Forward P/E 14.2653 1666.6667 GMED
PEG Ratio 1.7253 1.64 GKOS
Revenue Growth -0.7% 58.0% GKOS
Earnings Growth 18.2% 1896.3% GKOS
Tradestie Score 42.6/100 31.5/100 GMED
Profit Margin 17.8% -24.6% GMED
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY GMED

Relative Price Performance (Last 90 Days)

GMED 1M: -4.1% · 3M: -14.8% GKOS 1M: +47.6% · 3M: +34.3%

Current Technical Phase

GMED

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.7%), weak momentum, RSI 43

RSI (14): 43.0 · Price: $73.17

GKOS

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 70

RSI (14): 69.8 · Price: $247.86

Fundamentals Snapshot

Metric GMED GKOS
Market Cap — —
Forward P/E 14.1 176.5
Trailing P/E 18.5 —
Revenue (TTM) — —
Revenue Growth 0.0% 0.6%
Gross Margin 0.7% 0.8%
Operating Margin 0.2% 0.0%
EPS 4.06 -2.95
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, GMED is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.